DSIP

Delta Sleep-Inducing Peptide (DSIP) is a natural nonapeptide (a peptide consisting of nine amino acids) originally isolated from rabbit brain in 1977. It is primarily known for promoting slow-wave (delta) sleep and is found in both free and bound forms within the hypothalamus, pituitary, and peripheral tissues.

Key Benefits

• May support deeper, more restorative sleep quality
• Commonly researched for promoting relaxation and healthy sleep patterns
• May help support recovery by improving overnight restorative processes
• Research suggests potential benefits for stress management, mood balance, and overall well-being

FDA-Approved Uses

Regulatory status (as of May 2026):

• Previously: FDA Category 2 — compounding prohibited due to cited significant safety concerns including immunogenicity risk and absence of human safety data
• April 22, 2026: Removed from Category 2 following HHS Secretary directive
• PCAC review scheduled July 24, 2026 at FDA White Oak Campus
• Specific indications under evaluation: Opioid withdrawal, chronic insomnia, narcolepsy
• Public comments may be submitted to FDA docket FDA-2025-N-6895 by July 9, 2026
• If PCAC recommends Category 1 classification: Licensed 503A pharmacies will have a clear legal path to dispense DSIP for patient-specific prescriptions
• DOES NOT constitute FDA drug approval — Emideltide remains unapproved for any therapeutic use.

Approved in: No major regulatory authority has approved DSIP as a drug anywhere.

Conditions studied in research (mostly animal/small human studies):

Sleep disorders / chronic insomnia: Increases delta-wave EEG activity (slow-wave/deep sleep)

• Opioid and alcohol withdrawal: Russian literature; small human studies
• Narcolepsy: Under PCAC review consideration
• Stress and anxiety management: Some Russian/Soviet-era clinical data
• Pain modulation: Opioid-potentiating properties in animal models
• Depression: Limited early data
• Metabolic effects: GH release stimulation (indirect, via sleep quality improvement)

WADA status: Not listed on the WADA Prohibited List — a notable advantage for athletes managing sleep and recovery

Trade Names in the USA and Manufacturers

No FDA-approved trade name in the USA. No approved manufacturer.

Discovery history:

• First isolated in 1977 by Marcel Monnier and colleagues at the University of Basel (Switzerland) from the cerebral venous blood of rabbits subjected to EEG-monitored sleep stimulation
• Named for its apparent ability to increase delta (slow-wave) brain activity on EEG
• Found naturally in: Hypothalamus, limbic system, pituitary gland, peripheral tissues, and human breast milk
• A naturally occurring nonapeptide — unlike many research peptides which are entirely synthetic

US availability (as of May 2026)

• As of April 22, 2026: Category 2 designation removed — formal 503A rulemaking not yet complete
• After PCAC July 24, 2026 review (if favorable): Licensed 503A compounding pharmacies with valid physician prescription
• Research peptide vendors: Available as lyophilized powder (‘research use only’)
• Some US telehealth sleep clinics have begun offering it under emerging compounding access

Molecular identity

• Naturally occurring nonapeptide (9 amino acids)
• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
• MW: ~850 Daltons
• Highly sensitive to degradation at room temperature; cold-chain storage essential

Dosage

The following reflects research protocols and emerging clinical off-label use.

Subcutaneous injection (most common research route):

• Typical dose: 100–400 mcg per injection
• Common range: 200–300 mcg
• Frequency: Once daily, approximately 30–60 minutes before intended sleep
• Route: Subcutaneous (abdomen or thigh)

Intravenous (original research route; clinical setting):
100–300 mcg IV administered before sleep in original human studies

Cycling:
Typically used in short courses (5–14 days)
Break of 2–4 weeks before next course
Long-term continuous use not established as safe or effective

Opioid withdrawal protocol (Russian clinical literature):
Higher doses reported (up to 600–1,000 mcg) administered in structured withdrawal settings under medical supervision

Reconstitution:
Lyophilized powder; reconstitute with Bacteriostatic Water for Injection
Store lyophilized at -20°C or below
Reconstituted solution: Use within 24–48 hours refrigerated (highly sensitive to degradation)

Pricing

Research peptide vendors (unregulated):
Typical cost: $200–$400/month at standard research protocols
Per vial: ~$40–$100 depending on size

After potential Category 1 reclassification (pending PCAC July 2026):
Compounded DSIP from licensed 503A pharmacy: estimated ~$150–$350/month
Cash-pay only (insurance does not cover compounded unapproved compounds)

Stability warning: DSIP is notably sensitive to degradation. Price comparison should account for cold-chain shipping verification and CoA purity documentation. Degraded DSIP may be inert.

Tips

• Monitor the July 24, 2026 PCAC meeting outcome — FDA will specifically evaluate DSIP (Emideltide) for opioid withdrawal, chronic insomnia, and narcolepsy. A favorable Category 1 recommendation enables licensed 503A pharmacy access via physician prescription.
• DSIP does NOT induce sleep directly the way benzodiazepines, Z-drugs, or even melatonin do. It modulates sleep architecture — specifically increasing the proportion of time spent in slow-wave (delta) sleep once sleep occurs naturally. Patients expecting a sedating or hypnotic effect will be disappointed; the benefit is in sleep quality and depth, not sleep onset.
• WADA: DSIP is NOT prohibited — a genuine advantage for athletes seeking sleep quality improvement without anti-doping risk.
• Unlike benzodiazepines and Z-drugs (Ambien, etc.), DSIP is not associated with dependence, tolerance, or respiratory depression based on available data.
• DSIP was described as ‘incredibly safe’ in a 2001 European Journal of Anaesthesiology editorial (no lethal dose ever identified in animals; no significant human adverse events in published data). However, the FDA previously cited immunogenicity concerns — the July 2026 PCAC will re-evaluate this risk.
• Stability is critical: DSIP degrades rapidly in solution. Accept only products with cold-chain shipping and CoA purity ≥98%. Reconstitute just before use and administer within 24–48 hours.
• For opioid withdrawal support: DSIP should be considered an adjunct to, not a replacement for, evidence-based withdrawal management (buprenorphine/methadone MAT programs).

Side Effects

Very favorable safety profile based on available data — one of the more studied research peptides from a safety standpoint in early human trials.

From published human studies and research (original Swiss and Soviet-era data):
– Headache: Mild; most commonly reported human adverse event
– Nausea: Mild; occasional
– Dizziness / vertigo: Transient
– Daytime grogginess or sedation: Reported if taken during the day or at too-high doses
– Possible hormonal shifts: GH and cortisol modulation observed; clinical significance unclear at research doses

Safety profile standout:
– A 2001 European Journal of Anaesthesiology editorial described DSIP as ‘incredibly safe’: No lethal dose ever established in animal research; no significant serious adverse events reported in published human data

FDA’s stated concerns (reason for Category 2 designation):
– Immunogenicity: FDA cited theoretical risk of immune reactions to DSIP as a foreign peptide; no confirmed clinical cases of immunogenicity reported in published data
– Absence of comprehensive human safety data: FDA noted that no safety-related information identifying specific human risks had been identified — meaning insufficient data to declare safe, rather than confirmed evidence of harm

Key distinction: The FDA’s concerns were primarily about absence of data rather than confirmed adverse signals. Long-term safety in humans remains uncharacterized.

Contraindications

No formal FDA contraindications (no approved label).

Based on pharmacological properties and theoretical risks:
– Pregnancy and breastfeeding:
DSIP is found naturally in human breast milk; pharmacological significance of exogenous DSIP administration during breastfeeding is unknown. Not recommended during pregnancy (insufficient safety data).
– Severe psychiatric conditions (psychosis, mania): Serotonergic and GABAergic modulation may have unpredictable effects; use with caution
– Concurrent use of CNS depressants (benzodiazepines, opioids, Z-drugs, alcohol): Theoretical additive central depressant effects; use with caution
– HPA axis disorders (Cushing’s disease, Addison’s disease): DSIP modulates cortisol/ACTH signaling — may interact with HPA axis pathology
– Children: No safety data; not recommended
– Known hypersensitivity to DSIP or its components

Pharmacology

DSIP (Delta Sleep-Inducing Peptide; also Emideltide in FDA Federal Register) is a naturally occurring nonapeptide (9 amino acids) first isolated in 1977 from the cerebral venous blood of rabbits by Monnier et al. at the University of Basel. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. MW ~850 Daltons. A naturally endogenous peptide found in the hypothalamus, limbic system, pituitary gland, various peripheral tissues, and human breast milk.

Distinguishing pharmacological features:
– Unlike most research peptides, DSIP occurs naturally in the human body
– Not a sedative or hypnotic in the classical sense — does not force unconsciousness or impair wakefulness
– Acts as a sleep architecture modulator — increases proportion of slow-wave (delta) sleep
– Has opioid peptide potentiating properties — basis for withdrawal application
– Half-life: Not well-established in humans; estimated short (minutes in plasma); effects may last hours through downstream receptor modulation

Stability:
– Notable sensitivity to degradation at room temperature and in aqueous solution
– Requires strict cold-chain storage at -20°C lyophilized
– Reconstituted solution should be used within 24–48 hours
– Purity verification (CoA, HPLC ≥98%) is particularly important for this peptide

Mechanism of action

DSIP exerts effects through multiple overlapping neurological pathways:

1. GABAergic Modulation (primary sleep mechanism):
Acts on GABA-A receptors in hypothalamic and limbic regions — the same inhibitory pathway targeted by benzodiazepines and Z-drugs, but potentially at different binding sites or with different receptor subtype selectivity.
Effect: Shifts brain activity from arousal-promoting states toward slow-wave sleep patterns without the full sedative/amnestic/dependence profile of benzodiazepines.
2026 University of Basel research: DSIP modulates sleep architecture by increasing the proportion of time in slow-wave (delta) sleep after natural sleep onset — rather than inducing sedation directly.

2. HPA Axis Normalization:
DSIP modulates cortisol and ACTH secretion — normalizing HPA axis hyperactivity that is commonly dysregulated in chronic insomnia, stress, and addiction states.
Reduces stress-related cortisol elevation → facilitates transition to sleep-conducive hormonal milieu.

3. Serotonergic Modulation:
Interacts with serotonin pathways in the hypothalamus and raphe nuclei — contributing to sleep quality and mood stabilization.

4. Opioid Peptide Potentiation:
Enhances the activity of endogenous opioid peptides (enkephalins, endorphins) — basis for proposed opioid withdrawal support (reduces withdrawal severity by potentiating residual endogenous opioid tone).

5. GH Release (indirect):
By improving slow-wave sleep quality, DSIP may enhance the nocturnal GH pulse that occurs during deep sleep — not by directly stimulating GH secretion but by improving the sleep architecture that enables it.

Result Claims from Different Companies

No major pharmaceutical company has made commercial claims (no approved drug).

Original Swiss research (Monnier et al., 1977):
– First isolation and characterization of DSIP from rabbit cerebral venous blood
– Demonstrated EEG delta-wave increase following DSIP administration in rabbits
– Established the original sleep-inducing hypothesis

Soviet/Russian clinical literature (1980s–2000s):
– Small clinical studies demonstrated improvements in sleep quality, reductions in insomnia severity, and support during opioid withdrawal
– Data from structured opioid withdrawal programs: DSIP reduced subjective withdrawal severity and improved sleep during detoxification

2001 European Journal of Anaesthesiology (Pollard & Pomfrett editorial):
– Described DSIP as ‘incredibly safe’ based on absence of lethal dose in animal studies and no significant human adverse events in published literature
– Advocated for further clinical development

2026 University of Basel research (referenced in emerging 2026 literature):
– Confirmed DSIP modulates sleep architecture toward slow-wave sleep rather than inducing direct sedation
– Distinguished DSIP’s mechanism from classical hypnotics

ADDF (Alzheimer’s Drug Discovery Foundation) / HealingMaps (2026):
– Noted DSIP’s potential for treatment-resistant insomnia and opioid withdrawal as the primary clinically credible indications
– Noted the July 2026 PCAC evaluation for these specific indications

⚠️ The majority of positive clinical data originates from Soviet-era and small European studies. Large, well-designed RCTs do not exist. No FDA-reviewed clinical trial evidence exists for any indication.

Disclaimer

This content about “DSIP (Delta Sleep-Inducing Peptide) also known as Emideltide (FDA Federal Register) is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.